Pharmaceuticals, Biotechnology & Life Sciences

Merck’s Phase III success with sonesitatug vedotin shows first‑in‑class CLDN18.2‑targeted therapy for gastric cancer, offering new survival benefits and a clear value‑based pricing strategy.

Incyte’s latest executive option exercises reveal a strategic focus on TSR‑linked incentives and retention, hinting at confidence in growth while spotlighting dilution risks and competitive dynamics.

Explore how Sarepta’s new CEO and gene‑therapy strategies illuminate biotech market‑access, patent cliffs, and M&A trends for sustainable growth.

Lonza Group’s robust cell‑therapy manufacturing strategy—automation, global regulatory harmonization, and targeted M&A—drives growth and shields against upcoming patent cliffs.

IPSEN’s week‑long share buy‑back, 20‑26 July 2026, saw 6.85 m shares repurchased across Paris and Luxembourg, boosting EPS modestly while showcasing regulatory transparency and aggressive shareholder value tactics.

Explore AstraZeneca’s breakthrough Sone‑Ve ADC in CLDN18.2‑positive gastric cancer, its 2026 financial outlook, and strategic partnerships driving future growth.

Regeneron unveils linvoseltamab‑dupilumab combo for food allergies, backed by breakthrough data and a new TriNetX partnership that fuels real‑world evidence and faster FDA approval.

AbbVie’s upcoming earnings reveal how a new acquisition fuels R&D growth, regulatory strategy, and future cash flow amid Fed‑driven market volatility.

J&J’s $5.5 billion talc settlement shifts focus to high‑margin oncology, immunology and rare‑disease R&D while cutting legal risk and aligning with value‑based reimbursement.

Discover how AstraZeneca’s upcoming first‑half results will shape healthcare pricing, reimbursement, and operational strategy in 2024.